The technique, called pronuclear transfer, involves intervening in the fertilization process to remove faulty mitochondria capable of causing inherited fatal heart problems, liver failure, brain disorders, blindness and muscular dystrophy.
The treatment is referred to as “three-parent” in vitro fertilization because the babies are born from genetically modified embryos that have DNA from a mother, father and female donor.
Researchers conducted pre-clinical tests involving over 500 eggs from 64 donors and the technique showed potential to greatly reduce the level of faulty mitochondria in the embryo and prevent incurable inherited diseases.
They found no evidence that the technique harms early embryonic development.
Britain’s Human Fertilization and Embryology Authority will consider the results of the study to decide whether to issue the first license to a clinic.
More articles on supply chain:
Michael J. Fox Foundation and GE offer $25k in Parkinson’s research challenge
Cheaper breast cancer drug shows potential in clinical trial
Medtronic buys Responsive Orthopedics
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
